GILD.O (GILD.O) News
Follow GILD.O (GILD.O) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 2 public stories across 1 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Vir, Gilead team up on solid tumor cancer therapies in up to $1.9 billion deal
Oct 14 (Reuters) — Vir Biotechnology said on Wednesday it had signed a collaboration agreement worth up to $1.88 billion with Gilead Sciences to discover and develop new cancer treatments for solid tumors. Shares of Vir
EQUITY | Oct 14, 2026, 01:21 PM UTC
L
BUZZ — Vir Biotechnology gains after up to $1.9 billion licensing deal with Gilead
* Shares of Vir Biotechnology rise 11.7% to $11.85 premarket * Co inks collaboration and license agreement with Gilead for three candidates targeting selected solid tumor-associated antigens * VIR will be eligible to rec
EQUITY | Oct 14, 2026, 12:56 PM UTC